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(AROC > 0.9). Self-reported adherence was of low utility by 
itself. Hair level was the single best PK measure to predict 
EM-assessed adherence; the other measurements had lower 
discrimination values. Combining short-term (plasma) and 
long-term (hair) metrics could be useful to assess patterns 
of drug-taking in the context of PrEP.
Keywords PrEP drug-taking patterns of adherence 
electronic monitoring · Hair · Plasma
Introduction
According to UNAIDS, an estimated 2 million individuals 
acquired HIV in 2015 globally, with infection rates being 
highest in sub-Saharan Africa [1]. There is therefore an 
urgent need for effective methods to prevent ongoing trans-
mission of HIV. A number of clinical trials examining the 
efficacy of oral pre-exposure prophylaxis (PrEP) [2–6] with 
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) have 
been published in recent years. Results from these studies 
have been largely positive, indicate that PrEP prevents acqui-
sition of HIV infection when users are adherent [2, 4], and 
have led to broad recommendations for PrEP use worldwide 
[7].
Accurately measuring adherence to PrEP remains a chal-
lenge. In the HIV treatment setting, adherence is equally 
difficult to measure but viral loads can serve as a surrogate 
of adherence, unlike in the context of PrEP. Although mul-
tiple metrics of PrEP adherence have been investigated, 
there is no gold standard. Non-pharmacokinetic (non-PK) 
measures include self-report, pharmacy refills, pill counts, 
and electronic monitoring (EM; pill bottles that record each 
opening). Pharmacokinetic (PK) metrics are also available, 
such as monitoring drug levels in plasma, peripheral blood 
Abstract Measuring PrEP adherence remains challeng-
ing. In 2009–2010, the International AIDS Vaccine Initia-
tive randomized phase II trial participants to daily tenofovir 
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and best for hair (AROC 0.85). When combining hair with 
plasma or hair with self-report, discrimination was improved 
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mononuclear cells (PBMCs), dried blood spots (DBS), or 
hair. Various combinations of these measures have been used 
in the PrEP trials conducted to date, and recent papers have 
found different degrees of concordance among them [8–13]. 
Self-report is generally found to over-estimate adherence 
and correlate poorly with adherence determined by objec-
tive measures, such as drug levels in plasma, EM, and pill 
count [5, 9, 10]. In the International AIDS Vaccine Initia-
tive (IAVI) phase II trials of PrEP conducted among sero-
discordant couples in Uganda [13] and men who have sex 
with men (MSM) and female sex workers (FSW) in Kenya 
[14], modest associations were observed between PK meas-
ures (plasma, PBMC, and scalp hair levels) and adherence 
assessed by EM, but there was little correlation between 
self-report and drug levels in any matrix.
Discrepant results with different adherence measures 
could imply bias and/or inaccuracy with one or more of the 
measures. For instance, social desirability bias and recall 
error commonly limit the utility of self-reported adherence. 
EM may be inaccurate if individuals remove more than one 
pill per opening or do not remove any pills with an opening. 
Moreover, removing pills from a container may not neces-
sarily translate to drug ingestion. PK metrics are influenced 
by the half-life of the drug moiety and could be influenced 
by the timing of the sample draw relative to dosing (for 
short-term metrics), as well as biological and analytical 
variability in assay performance. Moreover, drug levels 
in different biomatrices such as hair and plasma measure 
adherence over different time periods and a patient may not 
be uniformly adherent over time. A significant limitation 
common to many comparisons of PK and non-PK meas-
ures is that the reporting periods are not always aligned. For 
example, a self-reporting period may be 1 month in duration 
and that period may be compared with a tenofovir concen-
tration in plasma, which reflects short-term drug ingestion 
(1–7 days). Tenofovir drug levels in PBMCs reflect ingestion 
over the moderate-term (7–14 days) and levels in hair and 
dried blood spots reflect ingestion over the long term (weeks 
to months). Finally, analyses comparing adherence measures 
in PrEP trials to date have also not yet explored the incre-
mental value of using multiple adherence measures, adjust-
ing them to reflect the same duration of PrEP use. Guidance 
for adherence measurement in PrEP trials, demonstrations 
projects and real world roll-out is therefore needed.
In this analysis, we provide a comprehensive assessment 
of multiple non-PK and PK adherence measures adjusted 
to align over a set duration of time within a phase II PrEP 
trial in two distinct populations: MSM and serodiscordant 
couples. We use short and long-term PK measures to assess 
patterns and concordance of adherence to PrEP over time. 
We also determine the incremental value of assessing multi-
ple adherence measures in combination (self-report and drug 
levels in plasma and hair) compared to EM.
Methods
Trial Setting and Participants
The phase II trial (conducted before the phase 3 trials 
showed efficacy of PrEP) was conducted at three of the 
IAVI-partner clinical research centres in Africa: the Medi-
cal Research Council/Uganda Virus Research Institute in 
Masaka, Uganda; the Kenya AIDS Vaccine Initiative in 
Kangemi, Nairobi, Kenya; and the KEMRI-Wellcome Trust 
Research Programme in Kilifi, Kenya. Eligible participants 
were HIV-negative adults aged 18–49 years. In Uganda, 
participants were HIV-uninfected partners in known HIV-
serodiscordant couple relationships and had self-reported 
unprotected sex with one or more HIV-infected partners not 
taking antiretroviral therapy (ART) in the past 3 months. 
Participants in Kenya were HIV-uninfected MSM and HIV-
uninfected FSW. Enrolment took place from October 2009 
through March 2010. The details of study procedures have 
been described previously [13, 14]. Briefly, eligible par-
ticipants were randomized to daily TDF/FTC or placebo 
or intermittent TDF/FTC (a fixed dose on Mondays and 
Fridays, and a post-coital dose within 2 h after sex, not to 
exceed one dose per day) or placebo in a 2:1:2:1 ratio. The 
trial objectives were to evaluate the safety and acceptabil-
ity of daily and intermittent dosing of TDF/FTC, measure 
adherence to the two dosing strategies via an array of met-
rics, and evaluate changes in HIV-associated risk behaviour 
with the two dosing strategies. Participants were followed 
at Weeks 1, 2, and 4 post-enrolment and then monthly for 4 
months with standardized adherence and HIV risk reduction 
counselling.
Adherence Assessment
Adherence in this study was measured via four methods: 
EM with the medication event monitoring system (MEMS, 
WestRock, Switzerland); self-reported taking of pills; and 
drug concentrations of tenofovir (TFV) in plasma and hair. 
EM data were downloaded from the MEMS at monthly 
study visits, and staff-related openings were removed from 
the dataset. Self-reported pill taking was assessed using a 
follow-back calendar method [15–17] over the time since 
the prior study visit. At clinic visits 8 and 16, the study 
staff and participant reviewed the memory aid completed 
by the participant in the last 28 days. The memory aid data 
were used to complete the calendar with the staff helping 
the participant to recall each day’s activity where necessary. 
MEMS opening and self-report were capped at one dose per 
day when there was more than one opening or self-reported 
pill-taking, respectively, on the same day. Plasma samples 
were collected every 4 weeks, with hair sampling at 8 and 
16 weeks. The procedures on sample handling and testing 
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for the PK methods are reported elsewhere [8]. The lower 
limits of detection for each PK measure were as follows: 
plasma TFV concentration 0.31 ng/ml and hair TFV con-
centration 0.002 ng/mg [8].
Statistical Analysis
We limited our analysis to participants receiving daily active 
drug in the IAVI trial and summarised participant charac-
teristics by counts and percentages. Data from Kenya were 
further limited to that from MSM participants because only 
five FSW (in whom behaviour and/or PK parameters may 
have differed from the MSM) participated. Missing data 
were excluded from analysis (i.e., no assumptions or imputa-
tions were performed). We aligned measures over equivalent 
dosing windows. For example, we used data for the 7 days 
prior to weeks 8 and 16 to compare plasma drug levels with 
EM and self-reported adherence. For comparisons with hair 
drug concentration, we used EM and self-reported adherence 
as recorded or reported over the 28 days prior to weeks 8 and 
16 (averaged by week).
We compared adherence measurements obtained at the 
8- and 16-week study visits. Analyses were stratified by 
study site, given socio-behavioral differences in the Kenyan 
and Ugandan populations, and higher adherence to study 
product in Uganda compared to Kenya as determined by 
five adherence measures in prior analyses [13, 14]. First, 
we categorised each of the adherence measures assessed in 
this study as low, moderate, and high, as shown in Table 1. 
The PK categorisations were based on the median values 
of each adherence measure from previous directly-observed 
therapy (DOT) studies, where TDF was administered to 
HIV-negative volunteers in a variety of dosing patterns to 
establish “adherence benchmarks” in the relevant biologi-
cal matrix, for hair [18] or plasma [19]. These cut-offs have 
been shown to be associated with clinical outcomes such as 
toxicities or seroconversion in other PrEP studies [20–24]. 
Medians were chosen over other potential thresholds (e.g., 
top tertile) because of the relatively small sample size, which 
can exaggerate the effect of outliers, and a high degree of 
inter- and intra-individual variability in drug metabolism. 
We estimated categorical concordance when both meas-
ures were matched (i.e., high–high, moderate–moderate, or 
low–low), expressed as a percentage. Additionally, Pearson 
correlation coefficients were calculated to determine cor-
relations between the different adherence measures using 
continuous values. For EM and self-report measures, the 
actual number of doses taken represented by self-report or 
MEMS opening were used for correlations.
To assess the incremental value of multiple adherence 
measures when used in combination, we compared dis-
tinct categories of EM adherence with the other adherence 
measures. We used a discriminant (C-statistic) analysis for 
single or combined methods for adherence measurement 
via logistic regression models with the outcome as binary 
(Table 1 moderate was combined with low and compared 
to high) and displayed by receiver operating characteristic 
(ROC) curve area. Data from both sites were combined due 
to sample size limitations. We also used univariate and mul-
tivariate linear models to show percentage variability (using 
models R-squared) between EM (continuous variable) and 
other adherence measures, either individually or in combi-
nation, taking in consideration repeated measures. While 
the accuracy of EM is potentially limited by pocket dosing 
(i.e., removal of multiple pills with one bottle opening) and 
curiosity openings (i.e., opening the bottle without remov-
ing pills), this measure has been shown to provide accurate 
estimates of day-to-day adherence behaviour [25, 26]. There-
fore, EM was chosen as the comparison (standard) in this 
analysis. Drug concentration levels were log-transformed 
for use in linear regression models. All PK concentrations in 
this study that were below the detection limit of each assay 
were set as equal to that limit, and the detection limit was 
added to all concentrations prior to log transformation. A 
separate analysis based on hair as the comparison (standard) 
as opposed to EM was performed.
Results
Participant Characteristics
Figure 1 shows the number of participants randomised, 
those missing PK samples at a given visit, and those ter-
minating the study early. Of the 139 participants rand-
omized in all sites (Uganda and Kenya) of the IAVI 
trial, 45 (32.4%) were assigned to daily active tenofovir/
emtricitabine and were therefore eligible for this analysis 
Table 1  Adherence categories 
for each of the five adherence 
metrics
MEMS medication event monitoring system, TFV tenofovir, TFV-DP tenofovir diphosphate
Adherence level MEMS Self-reported 
doses per week
Plasma TFV-DP (ng/ml) Hair TFV-DP (ng/mg)
Low 0– < 29% 0–2 ≤ 5.9 ≤ 0.012
Moderate 29– < 71% 3–5 > 5.9– < 52.2 > 0.012– < 0.038
High 71–100% 6–7 52.2 + 0.038 +
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[Uganda (N = 24) and Kenya (N = 21)]. Of these, 66.7% 
were male with a mean age of 29.2 years (standard devia-
tion [SD] 6.9).
Adherence Adjudicated by Each Measure by Time 
Frame
Median adherence in Ugandan participants was high by 
EM [7 openings per week, interquartile range (IQR) 6, 7], 
self-report (7 doses per week; IQR 7, 7), plasma (70.5 ng/
ml; IQR 38.9, 94.6), and hair (0.07 ng/mg; IQR 0.05, 
0.11). In Kenyan participants, median (IQR) adherence 
was as follows: moderate by EM [5 openings per week, 
interquartile range (IQR) 4, 7] and high by self-report (7 
doses per week; IQR 6, 7), plasma (81.0 ng/ml; IQR 40.0, 
148.2) and hair (0.07 ng/mg; IQR 0.03, 0.08).
Concordance Among Adherence Measures
As shown in Table 2, agreement was moderate to high with 
percent concordance of 63.6–93.3% among all measures 
at the Ugandan site. Agreement among measures at the 
Kenyan site was generally lower than in Uganda, ranging 
from 28.1–71.9%. Table 2 also indicates the direction of 
the discordance (i.e., higher or lower for each adherence 
measure compared to the others).  
Correlations Among Adherence Measures
In general, hair drug concentrations were most highly corre-
lated with EM adherence with coefficients of 0.41 in Uganda 
and 0.85 in Kenya (all p < 0.01). The correlation for plasma 
drug concentrations with EM adherence was similarly high 
for the Kenyan site (coefficient 0.68, p < 0.01), but lower 
for the Ugandan site (coefficient 0.20, p = 0.19). The cor-
relations between self-reported adherence and PK measures 
were poor at both sites with coefficients of − 0.43 to − 0.01 
(all p > 0.05). The correlations between hair and the plasma 
measures were moderate, ranging from 0.29 to 0.58 for both 
sites (p = 0.06, p < 0.01).
Incremental Value of Multiple Adherence Measures 
in Combination Compared to Electronic Monitoring
Figure 2 and Table 3 indicate the ability of each adherence 
measure individually or in combination to discriminate 
among high versus moderate or low EM adherence. Dis-
crimination was poor for the self-reported measure alone 
[area under receiver operating curve (AROC) 0.54, 95% 
CI 0.40–0.69] and best for the hair measure alone, AROC 
0.85, 95% CI 0.74–0.97. When combining two measures, 
discrimination improved with an AROC of > 0.9 for all 
combinations. The AROC was highest for a combination of 
self-report, hair, and plasma at an AROC = 0.999, leading 
Fig. 1  Study profile on ran-
domization and follow up of 
participants at both Uganda and 
Kenya sites
Acve (93)
Randomized (144)
Placebo (46)
Daily dosing (45) Intermient dosing (48) 
Uganda (24)  Kenya (21) 
Aended (23) 
Terminated early (1) 
Aended (19)
Data not available (1- Plasma)
8 weeks 
16 weeks Aended (19)
Data not available (1-hair, 2- Plasma)
Aended (22)
Data not available (1-hair, 1-Plasma)
Terminated early (1)
FSWs excluded from analysis (5) 
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to the optimal ROC curve for all possible combinations of 
measures (Fig. 2).
We determined the percent variability in EM adher-
ence explained by each of the other adherence measures 
individually or in combination. At both sites, hair as a sin-
gle adherence measure performed the best; hair explained 
17.0 and 41.0% of variability in EM adherence in Uganda 
and Kenya, respectively. In assessing combinations of 
Table 2  Concordance and correlations (Pearson’s coefficients) between non-PK and PK adherence measures among volunteers in Uganda 
(bold) and Kenya (italics)
Data reflect measurements at 8 and 16 weeks of follow-up for a total of 45 assessments in Uganda and 39 in Kenya
EM electronic monitoring, CC correlation coefficient
**Statistically significant p < 0.05
Methods Agreement EM Self-report Plasma Hair
CC N (%) CC N (%) CC N (%) CC N (%)
EM, N = 45 Concordant 1.0 1.0 0.02 9 (60.0) 0.68** 22 (68.8) 0.85** 23 (71.9)
Discordant (EM > other) 4 (26.7) 6 (18.7) 5 (15.6)
Discordant (EM < other) 2 (13.3) 4 (12.5) 4 (15.8)
Self-report, N = 21 Concordant 0.02 42 (93.3) 1.0 1.0 − 0.43** 7 (46.7) − 0.20 9 (28.1)
Discordant (SR > other) 2 (4.4) 3 (20.0) 8 (25.0)
Discordant (SR < other) 1 (2.2) 5 (33.3) 15 (46.9)
Plasma, N = 36 Concordant 0.20 31 (70.4) − 0.08 28 (63.6) 1.0 1.0 0.49** 18 (56.3)
Discordant (plasma > other) 13 (29.6) 1 (2.3) 7 (21.9)
Discordant (plasma < other) 0 (0.0) 15 (34.1) 7 (21.9)
Hair, N = 42 Concordant 0.41** 36 (81.8) − 0.01 37 (84.0) 0.29 31 (72.1) 1.0 1.0
Discordant (hair < other) 6 (13.6) 1 (2.3) 3 (7.0)
Discordant (hair < other) 2 (4.6) 6 (13.7) 9 (20.9)
Fig. 2  Maximal discrimination 
between high and moderate or 
low EM adherence based on 
a single alternate adherence 
measure or combinations of 
adherence measures
0.25
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0.75
1.00
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ty
0.00 0.25 0.50 0.75 1.00
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Self-report alone ROC area: 0.54, 95%CI: 0.40-0.69
Plasma alone ROC area: 0.69, 95%CI: 0.52-0.87
Hair alone ROC area: 0.85, 95%CI: 0.74-0.97
Self-report and plasma ROC area: 0.95, 95%CI: 0.79-0.99
Self-report and hair ROC area: 0.99, 95%CI: 0.85-0.99
Hair and plasma ROC area: 0.99, 95%CI: 0.88-0.99
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two adherence measures, the percent of explained vari-
ability improved and was highest for hair plus self-report 
in Uganda (17.4%) and hair plus plasma in Kenya (61.4%) 
Table 4. A combination of three measures (self-report, 
hair and plasma) did not provide a sizeable improvement 
compared to the highest shown by a combination of two 
measures [Uganda (20.0%) and Kenya (63.5%)]. Overall, 
the percent of variability in EM adherence explained by 
other adherence measures was lower in Uganda compared 
to Kenya.
In the separate analysis using hair as the standard com-
parison, similar patterns were observed as to when EM 
was used as the standard comparison). SR adherence per-
formed poorly [(AROC) 0.52, 95% CI 0.41–0.64 for dis-
crimination; 1.0 variability explained], whereas SR plus 
EM performed best [(AROC) 0.83, 95% CI 0.72–0.93 for 
discrimination; 53.8 variability explained].
Discussion
Among participants taking daily PrEP in a clinical trial, we 
described patterns of adherence to PrEP by combining short 
and long-term pharmacokinetic measures and aligning them 
with concurrent electronic data monitoring metrics and self-
reported adherence. We found evidence of consistently high 
adherence over different durations of time as assessed by 
multiple measures at both sites. In Kenya, the EM measure 
showed more moderate levels of adherence than in Uganda. 
Prior qualitative work with this population found that chal-
lenges, such as complexities of daily life, may have contrib-
uted to lower adherence for MSM [27].
We found mixed results in the concordance and correla-
tion analyses. Concordance was high in comparisons of self-
report, EM, and plasma and hair drug levels at the Ugan-
dan site, although more moderate concordance was seen 
among these measures at the Kenyan site. Interestingly, the 
correlations between measures were higher in the Kenyan 
population compared to the Ugandan population, although 
correlations were generally lower than concordance. This 
finding may reflect the distribution of the data and the man-
ner in which we created the PK categories for low, moderate, 
and high adherence. Our choice to use medians makes sense 
for this small study and the need to avoid the influence of 
outliers. However, values that fall just on either side of the 
medians may be misclassified, thus causing differences in 
analyses of concordance versus correlation. Furthermore, 
while the correlations are determined using data from these 
trials, the categorizations for concordance determination 
were based on median values from previous studies.
Importantly, limitations in the various adherence meas-
ures may have affected the accuracy of our comparisons. 
For instance, among the MSM at the Kenyan site, stigma 
[27] may have resulted in a reduced desire to use the EM 
device. Participants may have truly adhered to their medi-
cation through pocket dosing (e.g., opening the device and 
removing multiple pills on 1 day), thus resulting in high drug 
levels in plasma and hair, and decreased concordance of EM 
with other measures. Indeed, much of the discordance in this 
population reflected higher adherence as assessed by the PK 
measures and lower adherence as adjudicated by EM. Social 
desirability may have led to inaccuracies in self-reported 
adherence, as has been seen in multiple prior studies [25, 
28]. Additionally, drug concentration determinations may 
Table 3  Ability of each adherence measure individually or in com-
bination to discriminate among low, moderate, and high electronic 
monitoring adherence
Values indicate the C-statistic (area under the curve). Data from both 
sites were combined due to sample size limitations
Measure Area under the 
curve (AROC) 
95% CI
Single measure
 Self-report 0.54 (0.40–0.69)
 Plasma 0.69 (0.52–0.87)
 Hair 0.85 (0.74–0.97)
Combination of two measures
 Self-report + hair 0.99 (0.85–0.99)
 Plasma + hair 0.99 (0.88–0.99)
 Self-report + plasma 0.95 (0.79–0.99)
Combination of three measures
 Self-report + plasma + hair 0.99 (0.92–0.99)
Table 4  Electronic monitoring adherence compared to each of the 
other adherence measures individually or in combination (adjusting 
for different measures) using univariate and multivariate linear mod-
els
Measures Prediction of EM adherence
Uganda Kenya
Adjusted R Adjusted R
Single measure
 Self-report 0.0 0.0
 Plasma 3.9 41.9
 Hair 17.0 41.0
Combination of two measures
 Self-report + plasma 4.1 53.0
 Self-report + hair 17.4 40.6
 Plasma + hair 16.2 61.4
Combination of three measures
 Self-report + plasma + hair 20.0 63.5
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have been limited by variation in sample processing, dif-
ferences in metabolism within and between individuals, 
drug–drug interactions, and/or variable dose timing relative 
to sample collection (relevant only for plasma samples, in 
which the half-life of tenofovir is approximately 17 h) [8, 
10, 19].
A ROC analysis was used to determine the incremental 
value of combining multiple adherence measures in order to 
discriminate among low, moderate, and high EM adherence. 
As expected, we found that self-report alone performed 
poorly (AROC 0.54). This finding is similar to an analysis 
in the Ancillary Adherence Study within the Partners PrEP 
Study where discrimination of steady-state daily dosing ver-
sus less than steady state dosing for plasma tenofovir was 
poor for self-report (AROC 0.52). Our results indicate that 
hair drug levels offered the best discriminant ability (AROC 
0.85) as a single PK measure. This finding suggests that a 
long-term measure of adherence, as represented by hair lev-
els, can help summarize the day-to-day variability captured 
by the EM device. Using one PK measure plus self-report 
improved the discriminant ability to about 90% and a com-
bination of two PK metrics and self-report predicted the EM 
data even further. Differences in this analysis may exist by 
site, but the small sample size prevented site stratification.
In the regression analyses to predict variability in the EM 
adherence measure, hair drug levels explained the most vari-
ability at both sites, although plasma levels performed nearly 
as well in Kenya. The combination of hair and plasma drug 
concentrations explained nearly as much of the variability 
as combinations of three measures. This finding argues for 
combining short-term (e.g., plasma) and long-term (e.g., 
hair) measures to obtain a comprehensive picture of adher-
ence over time. The incremental value of the other adherence 
measures either singularly or in combination was higher in 
the Kenya site than the Uganda site. Reasons for this find-
ing are unclear, but could be related to the higher correla-
tions between measures at the Kenya site. Both approaches 
showed generally increasing ability to discriminate adher-
ence patterns with an increasing number of measures. How-
ever, the choice for the number of adherence measures used 
in a given study is dependent on resources and competing 
scientific priorities. Multiple measures may be most appro-
priate when an accurate assessment of adherence is needed 
for assessing biologic efficacy and/or triggering interven-
tions [29]. If only one measure can be employed, our analy-
sis suggests that either hair levels or EM monitoring can be 
used, with the former providing an overall measure adher-
ence and the latter indicating patterns.
The major strength of this analysis includes the inclusion 
of multiple adherence methods, including concurrent collec-
tion of both non-PK and PK measures. This data provide a 
rare opportunity for aligning the adherence measures over 
the same time period. Although there were differences in 
the comparisons among measures by site, the data taken as 
a whole show that correlations were highest between the 
EM measure and each of the PK measures, with hair levels 
exhibiting the best performance.
There are important limitations with this analysis. First, 
because we were interested in only the active arm of the 
two studies and the daily dosing strategy, the sample size 
was small and in some instance the data analyses could not 
be stratified by site. The small sample size limits us making 
conclusive assertions about the hypothesised results. There-
fore, the results of this analysis need to be interpreted with 
caution. Second, the sample was predominantly men, which 
could limit extrapolation of results to populations dominated 
by women. Third, we chose to use EM as the comparison 
standard for this analysis, as it has been previously shown to 
be an excellent measure for day-to-day adherence behaviour 
[25, 26]. It has also been shown to meaningfully discrimi-
nate between high rates of daily dosing compared to low 
rates [8]. Similar analyses could also be pursued to assess 
the ability to discriminate adherence per the PK measures. 
Finally, further investigations on PrEP adherence need to be 
carried out in routine care settings because adherence pat-
terns in a placebo-controlled trial environment could differ 
from the real-world setting where participants are taking a 
product already known to work.
In sum, this analysis indicates that objective measures 
of adherence are more informative than self-report and 
that employing multiple measures of adherence is likely to 
increase accuracy in estimating adherence behaviour. Spe-
cifically, the combination of adherence measures that reveal 
behaviour over the long-term (hair) plus another short-term 
measure (plasma) may be useful to assess patterns of drug-
taking. Important differences in measure performance, how-
ever, may arise in different populations and must be consid-
ered carefully for any study, most feasibly in the planning 
stage. Hair appears to be a good choice to include as an 
adherence measure where limited testing is available. Drug 
levels in dried blood spots also assess longer-term adher-
ence [30], but were not collected in this particular study. 
Given the importance of adherence in achieving effective 
protection against HIV with PrEP, these data provide valu-
able insights in the design of future prevention studies.
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